Dimitrios Zonios1, Hiroshi Yamazaki2, Norie Murayama2, Ven Natarajan3, Tara Palmore1, Richard Childs4, Jeff Skinner1, John E Bennett1. 1. National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, Maryland. 2. Showa Pharmaceutical University, Machida, Tokyo 194-8543, Japan. 3. SAIC-Frederick Inc, National Cancer Institute at Frederick, Maryland. 4. National Heart, Lung, and Blood Institute, NIH, Bethesda, Maryland.
Abstract
BACKGROUND: Prospective evaluation of the antifungal drug, voriconazole, is needed to determine whether drug toxicity correlates with CYP2C19 genotype or serum concentrations of voriconazole or its metabolites. METHODS: We conducted a prospective study of 95 patients to determine voriconazole toxicity and its relationship to genotype and serum levels of voriconazole and its two metabolites. Efficacy was not evaluated because, in most cases, the drug was given for empirical or prophylactic therapy. RESULTS: Hallucinations occurred in 16 patients (16.8%), visual changes in 17 (17.9%), photosensitivity in 10 (10.5%), and hepatotoxicity in 6 (6.3%). There was no correlation between photosensitivity or hepatotoxicity and levels of voriconazole or metabolites. Patients with hallucinations had higher average voriconazole levels (4.5 vs 2.5 μg/mL) but with extensive overlap. The recommended oral dose of 200 mg did not provide consistently detectable serum voriconazole levels in adults. CYP2C19 and CYP2C9 genotypes had a minor influence over levels, though the 4 patients homozygous for the 2C19*2 genotype had higher average levels for voriconazole (4.3 vs 2.5 μg/mL) and lower N-oxide levels (1.6 vs 2.5 μg/mL). CONCLUSIONS: CYP2C19 and 2C9 genotypes were not major determinants of voriconazole metabolism. No toxic serum level of voriconazole or its metabolites could be identified. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: Prospective evaluation of the antifungal drug, voriconazole, is needed to determine whether drug toxicity correlates with CYP2C19 genotype or serum concentrations of voriconazole or its metabolites. METHODS: We conducted a prospective study of 95 patients to determine voriconazoletoxicity and its relationship to genotype and serum levels of voriconazole and its two metabolites. Efficacy was not evaluated because, in most cases, the drug was given for empirical or prophylactic therapy. RESULTS:Hallucinations occurred in 16 patients (16.8%), visual changes in 17 (17.9%), photosensitivity in 10 (10.5%), and hepatotoxicity in 6 (6.3%). There was no correlation between photosensitivity or hepatotoxicity and levels of voriconazole or metabolites. Patients with hallucinations had higher average voriconazole levels (4.5 vs 2.5 μg/mL) but with extensive overlap. The recommended oral dose of 200 mg did not provide consistently detectable serum voriconazole levels in adults. CYP2C19 and CYP2C9 genotypes had a minor influence over levels, though the 4 patients homozygous for the 2C19*2 genotype had higher average levels for voriconazole (4.3 vs 2.5 μg/mL) and lower N-oxide levels (1.6 vs 2.5 μg/mL). CONCLUSIONS:CYP2C19 and 2C9 genotypes were not major determinants of voriconazole metabolism. No toxic serum level of voriconazole or its metabolites could be identified. Published by Oxford University Press on behalf of the Infectious Diseases Society of America 2014. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: Joyce Blaisdell; Lucia F Jorge-Nebert; Sherry Coulter; Stephen S Ferguson; Su-Jun Lee; Brian Chanas; Tina Xi; Harvey Mohrenweiser; Burhan Ghanayem; Joyce A Goldstein Journal: Pharmacogenetics Date: 2004-08
Authors: S Perea; G J Pennick; A Modak; A W Fothergill; D A Sutton; D J Sheehan; M G Rinaldi Journal: Antimicrob Agents Chemother Date: 2000-05 Impact factor: 5.191
Authors: S Trifilio; R Ortiz; G Pennick; A Verma; J Pi; V Stosor; T Zembower; J Mehta Journal: Bone Marrow Transplant Date: 2005-03 Impact factor: 5.483
Authors: Arwa Hassan; Jürgen Burhenne; Klaus-Dieter Riedel; Johanna Weiss; Gerd Mikus; Walter E Haefeli; David Czock Journal: Ther Drug Monit Date: 2011-02 Impact factor: 3.681
Authors: Michael J Dolton; John E Ray; Sharon C-A Chen; Kingsley Ng; Lisa G Pont; Andrew J McLachlan Journal: Antimicrob Agents Chemother Date: 2012-07-02 Impact factor: 5.191
Authors: T F Wang; T Wang; R Altman; P Eshaghian; J P Lynch; D J Ross; J A Belperio; S S Weigt; R Saggar; A Gregson; B Kubak; R Saggar Journal: Am J Transplant Date: 2009-10-21 Impact factor: 8.086
Authors: Brad Moriyama; Sameer Kadri; Stacey A Henning; Robert L Danner; Thomas J Walsh; Scott R Penzak Journal: Curr Fungal Infect Rep Date: 2015-04-16
Authors: B Moriyama; A Owusu Obeng; J Barbarino; S R Penzak; S A Henning; S A Scott; Jag Agúndez; J R Wingard; H L McLeod; T E Klein; S J Cross; K E Caudle; T J Walsh Journal: Clin Pharmacol Ther Date: 2017-04-18 Impact factor: 6.875
Authors: Joanna Lem; Muhammad Younus; Jalal A Aram; Shahrzad Moosavi; Klaus Freivogel; Anne Lewis; Rachel E Sobel Journal: Pharmaceut Med Date: 2019-04
Authors: Thomas F Patterson; George R Thompson; David W Denning; Jay A Fishman; Susan Hadley; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; M Hong Nguyen; Brahm H Segal; William J Steinbach; David A Stevens; Thomas J Walsh; John R Wingard; Jo-Anne H Young; John E Bennett Journal: Clin Infect Dis Date: 2016-06-29 Impact factor: 9.079